In the BioHarmony Drug Report Database
Sacituzumab govitecan
Trodelvy (sacituzumab govitecan) is an antibody pharmaceutical. Sacituzumab govitecan was first approved as Trodelvy on 2020-04-22. It is used to treat triple negative breast neoplasms in the USA. The pharmaceutical is active against tumor-associated calcium signal transducer 2.
Trade Name
|
Trodelvy |
|---|---|
Common Name
|
sacituzumab govitecan |
ChEMBL ID
|
CHEMBL3545262 |
Indication
|
triple negative breast neoplasms |
Drug Class
|
Monoclonal antibodies: humanized, tumors as target; antineoplastics (camptothecine derivatives) |
Image (chem structure or protein)
